For investors
A platform business, not a single-disease bet.
Neurology lacks continuous, objective biomarkers. NVT BVS is a minimally invasive, long-duration implant that provides continuous EEG. Epilepsy comes first: a large unmet need, established EEG physiology, a measurable endpoint, and a regulatory path. The same infrastructure potentially supports brain-state biomarkers across major neurological diseases.
The thesis
From a first indication to a platform.
01 Epilepsy
The first indication: an unmet need with a measurable endpoint.
02 FDA De Novo
The regulatory wedge for a novel monitoring device.
03 Platform
A continuous brain-state platform: the same implant, signal, and clinical workflow, built to extend.
Potential indications
- Parkinson’s
- Dementia
- Depression
- Sleep
- Brain injury
The opportunity
A narrow first indication.A neurology‑scale opportunity.
Where NVT begins
~3.4M
Americans live with epilepsy
~1M
have drug-resistant epilepsy, where NVT begins
Where the platform may reach
7.4M
live with Alzheimer’s dementia
21M
adults have a major depressive episode each year
~1.1M
live with Parkinson’s disease
50–70M
live with sleep and wake disorders
Approximate US affected populations. Conditions beyond epilepsy are potential future indications, not validated or approved uses.
The moat compounds with every layer.
01
Persistent access to high-quality, longitudinal brain physiology from a minimally invasive implant: data other platforms do not have.
02
Clinical validation and an FDA De Novo pathway, built in sequence. Evidence and regulatory work that takes years to reproduce.
03
Provider workflow, an emerging reimbursement framework, and accumulating disease-state datasets, each layer making the next harder to copy. Together, a superior, re-imagined way to care for chronic neurological disease.
Peer-reviewed science. A defined regulatory path.
2020
Founding validation
Subgaleal EEG validated against intracranial electrodes for seizure identification, published in the Journal of Clinical Neurophysiology.
2023
NIH-backed
NIH Blueprint MedTech funding and a preclinical implant study at the University of Colorado.
2024
NEJM review
Co-founder Dr. Daniel Friedman co-authors the NEJM review of wearable digital health technology for epilepsy.
2024
Recognized nationally
One of two companies selected at the Epilepsy Foundation's innovation competition.
The roadmap
Under 24 months to a pivotal FDA submission.
Epilepsy execution is the near-term focus. Every indication beyond it is a gated, separate decision. Full financials are in the investor brief.
A / B
Foundation
Requirements baseline through an integrated implant, edge, and cloud prototype.
C
Agentic Knowledge
Live in shadow mode alongside manual clinical review.
D / E
Development
Indication-specific development and design verification.
F
Clinical validation
Prospective evidence for the epilepsy claim, and the De Novo submission.
G / H
Commercial and extensions
Commercial readiness, then gated indication extensions.
An emerging reimbursement framework.
A dedicated family of CPT Category III codes for continuous sub-scalp EEG implantation and related procedures (0956T through 0960T) became effective in 2025, providing an emerging reimbursement framework for this category.
Built by clinicians and scientists who have spent careers on this exact signal.
Dr. Ruben Kuzniecky
Co-founder. Recipient of the American Epilepsy Society's Research and Recognition Award for clinical science.
Dr. Werner Doyle
Co-founder. Retired epilepsy neurosurgeon, now devoted to NVT's research and development.
Dr. Steven Pacia
Co-founder. First author of the founding study validating subgaleal EEG against intracranial EEG.
Dr. Daniel Friedman
Co-founder. Co-author of the New England Journal of Medicine review of wearable digital health technology for epilepsy.
Full leadership and advisory bios are available in the investor brief.
Request the full investor brief. Market model, clinical strategy, and financials.